Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer

Bibliography

• KIRN DH: Replication-selective microbiological agents: fighting cancer with germ warfare. Clin. Invest. (2000) 105:837–839.
   Google Scholar
• ROIZMAN B, KNIPE D: Herpes simplexviruses and their replication. In Fields virology 4th ed., vol. 2. Knipe DM & Howley PM (Eds.), Lippincott, Williams & Wilkins, Philadelphia, Pa. (2001): 2399–2460.
   Google Scholar
• MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL, COEN DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252:854–856.
   PubMed Web of Science ®Google Scholar
• FIELD HJ, WILDY P: The pathogenicity ofthymidine kinase-deficient mutants of herpes simplex virus in mice. j. Hyg. (London) (1978) 81:267–277.
   PubMedGoogle Scholar
• JAMIESON AT, GENTRY GA, SUBAK-SHARPE JH: Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. Gen. Vim]. (1974) 24:465–480.
   PubMed Web of Science ®Google Scholar
• FIELD HJ, DARBY G: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob. Agents Cheinother. (1980) 17:209–216.
   PubMed Web of Science ®Google Scholar
• TENSER RB, MILLER RL, RAPP F: Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science (1979) 205:915–917.
   PubMed Web of Science ®Google Scholar
• COEN DM, KOSZ-VNENCHAK M, JACOBSON JG et al.: Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA (1989) 86:4736–4740.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, MALICK A, COEN DM, MARTUZA RL: Reduction and eliminationof encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 32:597–603.
   PubMed Web of Science ®Google Scholar
• MINETA T, RABKIN SD, MARTUZA RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. (1994) 54:3963–3966.
   PubMed Web of Science ®Google Scholar
• CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma (1) 34.5, a gene nonessential for growth in culture. Science (1990) 250:1262–1266.
   Google Scholar
• MACLEAN AR, UL-FAREED M, ROBERTSON L, HARLAND J, BROWN SM: Herpes simplex virusType 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1and the 'a' sequence. " Gen. Virol. (1991) 72:631–639.
   PubMed Web of Science ®Google Scholar
• BOLOVAN CA, SAWTELL NM, THOMPSON RL: ICP34.5 mutants of herpes simplex virusType 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Vim/. (1994) 68:48–55.
   Google Scholar
• MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Merl (1995) 1:938–943.
   PubMed Web of Science ®Google Scholar
• HUNTER WD, MARTUZA RL, FEIGENBAUM F et al.: Attenuated, replication-competent herpes simplex virus Type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. (1999) 73:6319–6326.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene The,: (2000) 7:867–874.
   Web of Science ®Google Scholar
• RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Thec (2000) 7:859–866.
   Google Scholar
• SUNDARESAN P, HUNTER WD, MARTUZA RL, RABKIN SD: Attenuated, replication-competent herpes simplex virus Type 1 mutant G207: safety evaluation in mice. J. Virol. (2000) 74:3832–3841.
   PubMed Web of Science ®Google Scholar
• CHAMBERS R, GILLESPIE GY, SOROCEANU L et al.: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Nati Acad. ScL USA (1995) 92:1411–1415.
   PubMed Web of Science ®Google Scholar
• KESARI S, RANDAZZO BP, VALYI-NAGY T et al Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. (1995) 73:636–648.
   PubMed Web of Science ®Google Scholar
• ANDREANSKY SS, HE B,GILLESPIE GY et al.: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Nati Acad. Sci. USA (1996) 93:11313–11318.
   Google Scholar
• ANDREANSKY S, SOROCEANU L, FLOTTE ER et al.: Evaluation ofgenetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. (1997) 57:1502–1509.
   PubMed Web of Science ®Google Scholar
• RANDAZZO BP, KESARI S,GESSER RM et al.: Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology (1995) 211:94–101.
   Google Scholar
• KESARI S, LASNER TM, BALSARA KR et al.: A neuroattenuated ICP34.5-deficient herpes simplex virusType 1 replicates in ependymal cells of the murine central nervous system.' Gen. Virol. (1998) 79:525–536.
   Google Scholar
• LASNER TM, TAL-SINGER R, KESARI S, LEE VM,TROJANOWSKI JQ, FRASER NW: Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice.Neurovirol. (1998) 4:100–105.
   PubMed Web of Science ®Google Scholar
• MARKOVITZ NS, BAUNOCH D, ROIZMAN B: The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus if J. Virol. (1997) 71:5560–5569.
   PubMed Web of Science ®Google Scholar
• KRAMM CM, CHASE M, HERRLINGER U et al Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Tiler. (1997) 8:2057–2068.
   PubMed Web of Science ®Google Scholar
• PYLES RB, WARNICK RE, CHALK CL, SZANTI BE, PARYSEK LM: A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Then (1997) 8:533–544.
   PubMed Web of Science ®Google Scholar
• CHOU J, ROIZMAN B: The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Nati Acad. Sci. USA (1992) 89:3266–3270.
   Google Scholar
• CHOU J, CHEN JJ, GROSS M, ROIZMAN B: Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma (1)34.5- mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA (1995) 92:10516–10520.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RJ: Double-stranded RNA-activated protein kinase PKR. In Translational Control. Sonenberg N,Hershey JVVB & Mathews MB (Eds.), ColdSpring Harbor Laboratory Press, ColdSpring Harbor, NY (2000): 503–528.
   Google Scholar
• PETERS GA, KHOO D, MOHR I, SEN G: Inhibition of PACT mediated activation of PKR by the herpes simplex virus type 1 Usll protein. J. Virol (2002) 76:11054–11064.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER RJ, MOHR I: Translation initiation and viral tricks. Trends Biochem. Sci. (2003) In press.
   Google Scholar
• HE B, GROSS M, ROIZMAN B: The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase lalpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Nati Acad. Sci. USA (1997) 94:843–848.
   Google Scholar
• NOVOA I, ZENG H, HARDING HP, RON D: Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2 alpha. J. Cell Biol. (2001)153:1011–1022.
   PubMed Web of Science ®Google Scholar
• LEIB DA, MACHALEK MA, WILLIAMS BR, SILVERMAN RH, VIRGIN HW: Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Nati Acad. ScL USA (2000) 97:6097–6101.
   PubMed Web of Science ®Google Scholar
• MOHR I, GLUZMAN Y: A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. (1996) 15:4759–4766.
   PubMed Web of Science ®Google Scholar
• YORK IA, ROOP C, ANDREWS DW, RIDDELL SR, GRAHAM FL, JOHNSON DC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell (1994) 77:525–535.
   PubMed Web of Science ®Google Scholar
• MULVEY M, POPPERS J, LADD A, MOHR I: A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function. "(1999) 73:3375–3385.
   Google Scholar
• POPPERS J, MULVEY M, KHOO D, MOHR I: Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus Type 1 Usllprotein.Virol. (2000) 74:11215–11221.
   Web of Science ®Google Scholar
• KHOO D, PEREZ C, MOHR I: Characterization of RNA determinants recognized by the arginine- and proline-rich region of Us ii, a herpes simplex virusType 1 encoded double-stranded RNA bindingprotein that prevents PKR activation. .1. Viral. (2002) 76:11971–11981.
   PubMed Web of Science ®Google Scholar
• POPPERS J, MULVEY M, PEREZ C, KHOO D, MOHR I: Identification of a lytic Epstein-Barr virus gene product that can regulate PKR activation. J. Virol. (2003) 77:228–236.
   PubMed Web of Science ®Google Scholar
• CASSADY KA, GROSS M: The herpes simplex virus Type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain..1. Viral. (2002) 76:2029–2035.
   PubMed Web of Science ®Google Scholar
• MOHR I, STERNBERG D, WARD S, LEIB D, MULVEY M, GLUZMAN Y: Aherpes simplex virusType 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals..1. Viral. (2001) 75:5189–5196.
   Google Scholar
• TANEJA S, MACGREGOR J,MARKUS S, HA S, MOHR I: Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Nati Acad. Sci. USA(2001) 98:8804–8808.
   PubMed Web of Science ®Google Scholar
• TODO T, MARTUZA RL, RABKIN SD, JOHNSON PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA (2001) 98:6396–6401.
   PubMed Web of Science ®Google Scholar
• HILL A, JUGOVIC P, YORK I et al: Herpes simplex virus turns off theTAP to evade host immunity. Nature (1995) 375:411–415.
   PubMed Web of Science ®Google Scholar
• HE B, CHOU J, BRANDIMARTI R, MOHR I, GLUZMAN Y, ROIZMAN B:Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene.," Viral. (1997) 71:6049–6054.
   Google Scholar
• CHUNG RY, SAEKI Y, CHIOCCA EA: B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Vim/. (1999) 73:7556–7564.
   Google Scholar
• MEIGNIER B, LONGNECKER R, ROIZMAN B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. Infect. Dis. (1988) 158:602–614.
   Google Scholar
• MEIGNIER B, MARTIN B, WHITLEY RJ, ROIZMAN B: ha vivobehavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). .1. Infect. Dis. (1990) 162:313–321.
   Google Scholar
• ADVANI SJ, CHUNG SM, YAN SY et al: Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.Cancer Res. (1999) 59:2055–2058.
   PubMed Web of Science ®Google Scholar
• KNIPE DM, RUYECHAN WT, ROIZMAN B, HALLIBURTON IW:Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc. Nati Acad. Sci. USA (1978) 75:3896–3900.
   PubMedGoogle Scholar
• PARKER IN, GILLESPIE GY, LOVE CE, RANDALL S, WHITLEY RJ,MARKERT JM: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Nati Acad. Sci. USA (2000) 97:2208–2213.
   PubMed Web of Science ®Google Scholar
• ADVANI SJ, SIBLEY GS, SONG PY et al.:Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther: (1998) 5:160–165.
   PubMed Web of Science ®Google Scholar
• BRADLEY JD, KATAOKA Y, ADVANI S et al.: Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res.(1999) 5:1517–1522.
   PubMed Web of Science ®Google Scholar
• STANZIALE SF, PETROWSKY H, JOE JK et al.: Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery (2002) 132:353–359.
   PubMed Web of Science ®Google Scholar
• CHAHLAVI A, TODO T, MARTUZA RL, RABKIN SD:Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162–169.
   PubMedGoogle Scholar
• IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. (1999) 5:881–887.
   PubMed Web of Science ®Google Scholar
• KEDA K, WAKIMOTO H, ICHIKAWA T et al.: Complement depletion facilitates theinfection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. (2000) 74:4765–4775.
   PubMed Web of Science ®Google Scholar
• JORGENSEN TJ, KATZ S, WITTMACK EK et al.: Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (2001) 3:451–456.
   PubMed Web of Science ®Google Scholar
• WU A, MAZUMDER A, MARTUZA RL et al.: Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.Cancer Res. (2001) 61:3009–3015.
   PubMed Web of Science ®Google Scholar
• WALKER JR, MCGEAGH KG, SUNDARESAN P, JORGENSEN TJ, RABKIN SD, MARTUZA RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vectorG207. Hum. Gene Ther: (1999) 10:2237–2243.
   Google Scholar
• WONG RJ, JOE JK, KIM SH, SHAH JP, HORSBURGH B, FONG Y: Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Thec(2002) 13:1213–1223.
   PubMed Web of Science ®Google Scholar
• HERRLINGER U, KRAMM CM, ABOODY-GUTERMAN KS et al.: Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. (1998) 5:809–819.
   PubMed Web of Science ®Google Scholar
• CHAHLAVI A, RABKIN S, TODO T, SUNDARESAN P, MARTUZA R: Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. (1999) 6:1751–1758.
   PubMed Web of Science ®Google Scholar
• DELMAN KA, BENNETT JJ, ZAGER JSet al: Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther: (2000) 11:2465–2472.
   PubMed Web of Science ®Google Scholar
• TODA M, RABKIN SD, KOJIMA H, MARTUZA RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Thec (1999) 10:385–393.
   PubMed Web of Science ®Google Scholar
• TODO T, RABKIN SD, SUNDARESAN P et al.: Systemic antitumor immunity in experimental braintumor therapy using a multimutated, replication-competent herpes simplex virus.Hum. Gene EMT. (1999) 10:2741–2755.
   Google Scholar
• PAPANASTASSIOU V, RAMPLING R, FRASER M et al.: The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther: (2002) 9:398–406.
   Google Scholar
• MACKIE RM, STEWART B, BROWN SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 357:525–526.
   PubMed Web of Science ®Google Scholar
• CASSADY KA, GROSS M, GILLESPIE GY, ROIZMAN B: Second-site mutation outside of the Us10-12 domain of 4734.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence. Virol (2002) 76:942–949.
   Google Scholar
• GOLDSMITH K, CHEN W, JOHNSON DC, HENDRICKS RL: Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. Exp. Med. (1998) 187:341–348.
   PubMed Web of Science ®Google Scholar
• AHN K, MEYER TH, UEBEL S et al.: Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. (1996) 15:3247–3255.
   PubMed Web of Science ®Google Scholar